MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Balance Sheet 2011-2026 | ADMP
Annual Balance Sheet Adamis Pharmaceuticals Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-22.5 M | 3.12 K | -4.73 M | -16.7 M | -12.3 M | 3.31 M | -4.08 M | -4.98 M | 1.18 M | 294 K | 25.3 K | |
Long Term Debt |
- | 343 K | 891 K | - | - | 2.58 M | 3.07 M | - | - | - | - | - |
Long Term Debt Current |
343 K | 350 K | 493 K | 440 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 7.44 M | 1.59 M | 113 K | 3.07 M | 3.9 M | - | - | - | - | - |
Total Current Liabilities |
11.4 M | 11.2 M | 19.9 M | 10.2 M | 11.6 M | 8.79 M | 8.61 M | 2.75 M | 3.39 M | 4.68 M | 2.89 M | - |
Total Liabilities |
11.6 M | 12.4 M | 27.4 M | 11.8 M | 11.7 M | 11.9 M | 12.5 M | 2.75 M | 2.93 M | 4.68 M | 2.89 M | 3.11 M |
Deferred Revenue |
27.8 K | 100 K | 100 K | 916 K | 1.01 M | 14.8 K | 54.5 K | - | - | - | - | - |
Retained Earnings |
-305 M | -278 M | -230 M | -182 M | -153 M | -114 M | -88.5 M | -69 M | -46.1 M | -38 M | -30.8 M | -25.9 M |
Total Assets |
10.9 M | 38.3 M | 30.9 M | 47.8 M | 58.4 M | 51.4 M | 37.8 M | 12.1 M | 15.1 M | 351 K | 169 K | 1.73 M |
Cash and Cash Equivalents |
1.08 M | 23.2 M | 6.86 M | 8.81 M | 19.3 M | 17.3 M | 4.09 M | 4.08 M | 3.77 M | - | 7.52 K | 1.24 M |
Book Value |
-651 K | 25.9 M | 3.5 M | 36 M | 46.7 M | 39.5 M | 25.3 M | 9.31 M | 12.2 M | -4.33 M | -2.72 M | -1.38 M |
Total Shareholders Equity |
-808 K | 25.9 M | 3.5 M | 33 M | 46.7 M | 39.5 M | 25.3 M | 9.31 M | 9.5 M | -4.33 M | -2.72 M | -1.38 M |
All numbers in USD currency
Quarterly Balance Sheet Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 63.2 K | 157 K | 250 K | 343 K | 432 K | 1.57 M | 2.03 M | 891 K | 1.42 M | 1.96 M | 386 | 1.54 K | 2.21 M | 1.54 K | 1.54 K | - | 2.71 M | 2.83 M | 2.95 M | 3.07 M | 3.19 M | 3.3 M | 3.42 M | 3.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.9 M | 18.6 M | 11.6 M | 9.13 M | 10.7 M | 14.6 M | 12.4 M | 10.6 M | 17 M | 25.5 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 14.8 M | 11.8 M | 11.8 M | 11.8 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 2.75 M | 2.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
173 K | 27.8 K | 27.8 K | 27.8 K | 100 K | 100 K | 100 K | 100 K | 104 K | 121 K | 100 K | 100 K | 100 K | 100 K | 116 K | 116 K | 116 K | 916 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | 14.8 K | 14.8 K | 10.9 K | 14.8 K | 54.5 K | 54.5 K | 54.5 K | 54.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-323 M | -314 M | -305 M | -301 M | -297 M | -288 M | -278 M | -269 M | -257 M | -248 M | -230 M | -230 M | -230 M | -230 M | -181 M | -182 M | -182 M | -182 M | -153 M | -153 M | -153 M | -153 M | -114 M | -114 M | -114 M | -114 M | -88.5 M | -88.5 M | -88.5 M | -88.5 M | -69 M | -69 M | -69 M | -69 M | -55.4 M | -55.4 M | -55.4 M | -55.4 M | -44.6 M | -39.1 M | -39 M | -38 M | -36.3 M | -34.4 M | -33.5 M | -30.8 M | -29.6 M | -28.6 M | -27.1 M | -25.9 M |
Total Assets |
8.96 M | 9.08 M | 10.9 M | 12.1 M | 17.7 M | 30.5 M | 38.3 M | 45.1 M | 63.7 M | 80.7 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | 58.4 M | 58.4 M | 58.4 M | 58.4 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 14.8 M | 3.52 M | - | 351 K | 921 K | 764 K | 1.8 M | 169 K | 249 K | 371 K | 688 K | 1.73 M |
Cash and Cash Equivalents |
6.66 M | 3.1 M | 1.08 M | 2.42 M | 8.88 M | 17.8 M | 23.2 M | 28.7 M | 40.3 M | 57.6 M | 6.75 M | 6.75 M | 6.86 M | 6.86 M | 8.81 M | 8.81 M | 8.81 M | 8.81 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 4.09 M | 4.09 M | 4.09 M | 4.09 M | 4.08 M | 4.08 M | 4.08 M | 4.08 M | 3.77 M | 3.77 M | 2.13 M | 5.4 M | 4.67 M | 120 K | 3.4 M | - | 1.42 K | 10.1 K | 720 K | 7.52 K | 1.6 K | 3.03 K | 191 K | 1.24 M |
Book Value |
-4.96 M | -9.52 M | -651 K | 3 M | 7.04 M | 15.9 M | 25.9 M | 34.5 M | 46.7 M | 55.2 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 33 M | 36 M | 36 M | 36 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 9.31 M | 9.31 M | 12.1 M | 12.1 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 14.8 M | 3.52 M | - | 351 K | 921 K | 764 K | 1.8 M | 169 K | 249 K | 371 K | 688 K | 1.73 M |
Total Shareholders Equity |
-5.29 M | -9.68 M | -808 K | 2.85 M | 7.04 M | 15.9 M | 25.9 M | 34.5 M | 46.7 M | 55.2 M | 5.98 M | 3.5 M | 3.5 M | 3.5 M | 33 M | 36 M | 36 M | 36 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 9.31 M | 9.31 M | 9.31 M | 9.31 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 10.1 M | -4.93 M | -4.98 M | -4.33 M | -3.24 M | -5.07 M | -4.25 M | -2.72 M | -2.25 M | -2.02 M | -1.23 M | -1.38 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Adamis Pharmaceuticals Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Drug manufacturers
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
$ 1.14 | -4.62 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
$ 2.56 | 1.24 % | $ 1.35 B | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
$ 4.74 | 1.94 % | $ 66.6 M | USA |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
$ 11.08 | 0.82 % | $ 567 M | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
$ 5.05 | -2.88 % | $ 313 M | USA |
 |
Harrow Health
HROW
|
$ 47.49 | -0.86 % | $ 1.55 B | USA |
 |
China Pharma Holdings
CPHI
|
$ 1.25 | - | $ 21.8 M |  China |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
$ 1.62 | 0.62 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
$ 6.75 | -3.3 % | $ 2.46 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Canada |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
$ 1.58 | -2.17 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
$ 3.64 | -3.96 % | $ 479 M | USA |
 |
Pacira BioSciences
PCRX
|
$ 19.43 | 1.38 % | $ 899 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
$ 21.51 | 0.14 % | $ 2.05 B |  France |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
$ 15.06 | 0.2 % | $ 2.07 B | USA |
 |
Aurora Cannabis
ACB
|
$ 4.14 | -2.13 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
$ 1.22 | 27.44 % | $ 28.5 M | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
$ 3.33 | 1.06 % | $ 4.13 M | USA |
 |
Relmada Therapeutics
RLMD
|
$ 3.93 | 5.01 % | $ 118 M | USA |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
$ 12.04 | 4.88 % | $ 855 M | USA |
 |
Tilray
TLRY
|
$ 8.74 | -7.62 % | $ 5.4 B | Canada |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
$ 5.59 | 2.19 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
$ 0.65 | -0.68 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | USA |
 |
Veru
VERU
|
$ 2.53 | -5.95 % | $ 341 M | USA |
 |
TherapeuticsMD
TXMD
|
$ 2.55 | 14.39 % | $ 26.6 M | USA |
 |
Viatris
VTRS
|
$ 12.66 | -1.59 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | USA |
 |
cbdMD
YCBD
|
$ 0.83 | -9.94 % | $ 3.58 M | USA |